Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
All content for The Swiss Connection is the property of SWI swissinfo.ch and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
Switzerland and Silicon Valley: EP6 Sherry Wong ‘Living in a society where capital is strong and the welfare state is weak‘
The Swiss Connection
24 minutes
1 year ago
Switzerland and Silicon Valley: EP6 Sherry Wong ‘Living in a society where capital is strong and the welfare state is weak‘
Send us a text For artist and researcher Şerife (Sherry) Wong the popular image of visionary geniuses who change the world from their garages is an illusion. “We are idealising the myth of the inventor, the American dream of the man who, from nothing, becomes super rich and changes the world for the better, but...for whom?” asks Wong, who studies the social implications of emerging technologies. She is also an affiliate research scientist at the University of California, Berkeley. You can fi...
The Swiss Connection
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
